Company Overview and News

 
Demand for CPO expected to pick up towards 4Q of 2018

2018-09-14 theedgemarkets
Plantation sector Maintain neutral: Malaysia’s crude palm oil (CPO) production increased for a second straight month in August, rising by 7.9% month-on-month (m-o-m) to 1.62 million tonnes. The fresh fruit bunch (FFB) yield also improved across Peninsular Malaysia, Sabah and Sarawak, rising by 8.7%, 3.2% and 12.6% year-on-year (y-o-y) respectively to 1.38 tonnes/ha, 1.28 tonnes/ha and 1.52 tonnes/ha.
KLKBY 2445 5138 2216 4383 2291 4243 5012

 
WTK returns to the black in 2Q on higher contribution from timber division

2018-08-30 theedgemarkets
KUALA LUMPUR (Aug 30): WTK Holdings Bhd has returned to the black with a net profit of RM1.21 million for the second quarter ended June 30, 2018 (2QFY18), compared to a net loss of RM12.55 million in the same quarter last year, on higher contribution from the timber division.
BSMAF 4243 1818

 
Further increase in export prices of plywood seen

2018-06-11 thestar.com.my
Export prices for Sarawak plywood products to Japan have risen over 10% since late last year, and further increases are on the cards.
4243 5012

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...